In our opinion, when weighing the use of SGLT2 inhibitors in T1D for the treatment of asymptomatic HF, it is essential to establish strategies to reduce the risk of DKA, ideally with the involvement of specialized multidisciplinary units. Here, SLC5A2 is linked to type 1 diabetes mellitus.